SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 74 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $13,000 | +18.2% | 1,423 | -45.9% | 0.00% | – |
| Q1 2019 | $11,000 | 0.0% | 2,628 | 0.0% | 0.00% | – |
| Q4 2018 | $11,000 | -42.1% | 2,628 | +10.1% | 0.00% | -100.0% |
| Q3 2018 | $19,000 | -17.4% | 2,388 | -26.7% | 0.00% | -50.0% |
| Q2 2018 | $23,000 | -51.1% | 3,256 | -0.8% | 0.00% | – |
| Q1 2018 | $47,000 | +487.5% | 3,281 | +244.6% | 0.00% | – |
| Q4 2017 | $8,000 | -71.4% | 952 | +27.3% | 0.00% | -100.0% |
| Q3 2017 | $28,000 | -24.3% | 748 | -71.7% | 0.00% | -50.0% |
| Q2 2017 | $37,000 | +825.0% | 2,641 | +911.9% | 0.00% | – |
| Q1 2017 | $4,000 | – | 261 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |